C

Cyclopharm Ltd
ASX:CYC

Watchlist Manager
Cyclopharm Ltd
ASX:CYC
Watchlist
Price: 1.38 AUD 0.73% Market Closed
Market Cap: 153.4m AUD
Have any thoughts about
Cyclopharm Ltd?
Write Note

Cyclopharm Ltd
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Cyclopharm Ltd
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
C
Cyclopharm Ltd
ASX:CYC
Long-Term Debt
AU$4.7m
CAGR 3-Years
2%
CAGR 5-Years
0%
CAGR 10-Years
N/A
R
Respiri Ltd
ASX:RSH
Long-Term Debt
AU$57.4k
CAGR 3-Years
-7%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ImpediMed Ltd
ASX:IPD
Long-Term Debt
AU$810k
CAGR 3-Years
72%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cochlear Ltd
ASX:COH
Long-Term Debt
AU$202.1m
CAGR 3-Years
-5%
CAGR 5-Years
3%
CAGR 10-Years
-1%
Optiscan Imaging Ltd
ASX:OIL
Long-Term Debt
AU$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
EMvision Medical Devices Ltd
ASX:EMV
Long-Term Debt
AU$1.8m
CAGR 3-Years
247%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Cyclopharm Ltd
Glance View

Market Cap
153.4m AUD
Industry
Health Care

Cyclopharm Ltd. is a radiopharmaceutical company, which engages in the diagnostic imaging in lung health. The company provides diagnostic imaging services specializing in lung health. The firm through its medical device and pharmaceutical products under the name of Technegas, which has become the industry in diagnostic functional lung imaging technology. The company distributes its products in approximately 60 countries throughout the world with over 1500 nuclear medicine departments utilizing Technegas. The firm formed a joint venture with Alfred Health Solutions and Macquarie University Hospital to provide various imaging services on-site at the hospital. The Macquarie Medical Imaging (MMI) offers a range of diagnostic radiology, interventional radiology, nuclear medicine and molecular imaging services for inpatient and outpatients. Its Ultralute is a device that extends the useful life of Molybdenum-99 (Mo-99) generators.

CYC Intrinsic Value
2.01 AUD
Undervaluation 31%
Intrinsic Value
Price
C

See Also

What is Cyclopharm Ltd's Long-Term Debt?
Long-Term Debt
4.7m AUD

Based on the financial report for Jun 30, 2024, Cyclopharm Ltd's Long-Term Debt amounts to 4.7m AUD.

What is Cyclopharm Ltd's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
0%

Over the last year, the Long-Term Debt growth was 15%. The average annual Long-Term Debt growth rates for Cyclopharm Ltd have been 2% over the past three years .

Back to Top